MX2021001527A - Proteínas de unión a nkg2d, cd16 y a un antígeno asociado a tumor. - Google Patents

Proteínas de unión a nkg2d, cd16 y a un antígeno asociado a tumor.

Info

Publication number
MX2021001527A
MX2021001527A MX2021001527A MX2021001527A MX2021001527A MX 2021001527 A MX2021001527 A MX 2021001527A MX 2021001527 A MX2021001527 A MX 2021001527A MX 2021001527 A MX2021001527 A MX 2021001527A MX 2021001527 A MX2021001527 A MX 2021001527A
Authority
MX
Mexico
Prior art keywords
tumor
associated antigen
proteins binding
binding nkg2d
nkg2d
Prior art date
Application number
MX2021001527A
Other languages
English (en)
Inventor
Asya Grinberg
Bianka Prinz
Gregory P Chang
Ann F Cheung
William Haney
Bradley M Lunde
Jinyan Du
Original Assignee
Dragonfly Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dragonfly Therapeutics Inc filed Critical Dragonfly Therapeutics Inc
Publication of MX2021001527A publication Critical patent/MX2021001527A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se describen proteínas de unión multiespecíficas que se unen al receptor NKG2D, CD16, y a un antígeno asociado a tumor seleccionado de c-MET, KIT, F3, IGF1R, Lewis Y, MUC13, MUC4, MCAM, LRRC32, sialil-Tn, gpA33, GD3, GM2, EPHA3, TNFRSF10A, TNFSF11, CD74, y PMEL, así como también composiciones farmacéuticas y métodos terapéuticos útiles para el tratamiento de cáncer.
MX2021001527A 2018-08-08 2019-08-08 Proteínas de unión a nkg2d, cd16 y a un antígeno asociado a tumor. MX2021001527A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862716110P 2018-08-08 2018-08-08
PCT/US2019/045677 WO2020033664A1 (en) 2018-08-08 2019-08-08 Proteins binding nkg2d, cd16 and a tumor-associated antigen

Publications (1)

Publication Number Publication Date
MX2021001527A true MX2021001527A (es) 2021-06-15

Family

ID=69415105

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021001527A MX2021001527A (es) 2018-08-08 2019-08-08 Proteínas de unión a nkg2d, cd16 y a un antígeno asociado a tumor.

Country Status (13)

Country Link
US (1) US20220153848A1 (es)
EP (1) EP3833385A4 (es)
JP (1) JP7482363B2 (es)
KR (1) KR20210078473A (es)
CN (1) CN113164570B (es)
AU (1) AU2019318087A1 (es)
BR (1) BR112021002276A2 (es)
CA (1) CA3108646A1 (es)
IL (1) IL280618A (es)
MA (1) MA53284A (es)
MX (1) MX2021001527A (es)
SG (1) SG11202101298XA (es)
WO (1) WO2020033664A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019218136A1 (en) 2018-02-08 2020-08-13 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor
CA3240527A1 (en) * 2021-12-16 2023-06-22 Universitat Basel Discernible cell surface protein variants of cd117 for use in cell therapy
WO2024008910A1 (en) 2022-07-07 2024-01-11 Cimeio Therapeutics Ag Antibodies targeting cd117

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR074439A1 (es) 2008-12-02 2011-01-19 Pf Medicament Anticuerpo anti-cmet (receptor c-met)
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
UY32808A (es) 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
UY33492A (es) * 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
CN107936121B (zh) * 2011-05-16 2022-01-14 埃泰美德(香港)有限公司 多特异性fab融合蛋白及其使用方法
GB201203442D0 (en) * 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
GB2519786A (en) * 2013-10-30 2015-05-06 Sergej Michailovic Kiprijanov Multivalent antigen-binding protein molecules
KR102603417B1 (ko) 2014-05-06 2023-11-20 제넨테크, 인크. 포유동물 세포를 사용한 이종다량체 단백질의 생산
NZ733580A (en) 2015-01-02 2024-02-23 Takeda Pharmaceuticals Co Bispecific antibodies against plasma kallikrein and factor xii
EP3313876A2 (en) 2015-06-23 2018-05-02 Innate Pharma Multispecific antigen binding proteins
US20180327499A1 (en) * 2015-11-13 2018-11-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti- nkg2d single domain antibodies and uses thereof
CA3016563A1 (en) * 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
CA3090236A1 (en) * 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells

Also Published As

Publication number Publication date
BR112021002276A2 (pt) 2021-05-04
WO2020033664A1 (en) 2020-02-13
US20220153848A1 (en) 2022-05-19
KR20210078473A (ko) 2021-06-28
IL280618A (en) 2021-03-25
MA53284A (fr) 2022-01-26
CN113164570A (zh) 2021-07-23
AU2019318087A1 (en) 2021-03-04
CA3108646A1 (en) 2020-02-13
JP7482363B2 (ja) 2024-05-14
JP2021533159A (ja) 2021-12-02
CN113164570B (zh) 2024-05-14
SG11202101298XA (en) 2021-03-30
EP3833385A1 (en) 2021-06-16
EP3833385A4 (en) 2021-12-22

Similar Documents

Publication Publication Date Title
MX2020012130A (es) Proteinas multiespecificas de union de direccionamiento a anhidrasa carbonica 9 (caix), anoctamina-1 (ano1), mesotelina, antigeno de superficie celular de trofoblasto (trop2), antigeno carcinoembrionario (cea) o claudina-18.2.
MX2021001527A (es) Proteínas de unión a nkg2d, cd16 y a un antígeno asociado a tumor.
MX2021001510A (es) Proteínas de union a nkg2d, cd16, y un antígeno asociado a tumores.
MX2021002970A (es) Proteinas de union a nkg2d, cd16 y un antigeno asociado a tumor.
EP3882270A3 (en) Proteins binding nkg2d, cd16, and egfr, ccr4, or pd-l1
MX2019009468A (es) Proteínas de unión multiespecíficas para la activación de células asesinas naturales y usos terapéuticos de las mismas para tratar cáncer.
MX2019009566A (es) Proteinas de union a bcma, nkg2d y cd16.
EP4273258A3 (en) Proteins binding her2, nkg2d and cd16
MX2020002036A (es) Proteinas de union a nkg2d, cd16 y un antigeno asociado al tumor.
MX2022004430A (es) Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), al cumulo de diferenciacion 16 (cd16) y a la tirosina cinasa 3 similar a fms (flt3).
MX2022013944A (es) Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a).
MX2021009259A (es) Conjugados de il-2 y metodos de uso del mismo.
MX2019009541A (es) Proteinas que se unen a psma, nkg2d y cd16.
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
MX2020008075A (es) Anticuerpos anti-ctla4 y métodos para elaborarlos y usarlos.
AU2018271930A1 (en) A protein binding NKG2D, CD16 and a tumor-associated antigen
WO2017087678A3 (en) Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
AU2018273250A1 (en) A protein binding NKG2D, CD16 and a tumor-associated antigen
MX2020008333A (es) Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales.
WO2017069958A3 (en) Modulation of novel immune checkpoint targets
MX2022005404A (es) Compuestos de fijación a il-2r e il-7r dual.
WO2017053469A3 (en) Cd3 binding polypeptides
MX2019009943A (es) Proteínas que se unen a gd2, nkg2d y cd16.
MX2022001776A (es) Terapias de combinacion de inmuno oncologia con conjugados de il-2.
MX2022002111A (es) Novedosos anticuerpos anti-cldn18.2.